Department of Obstetrics and Gynecology, Jichi Medical University, Saitama Medical Center, Saitama, Japan
Department of Obstetrics and Gynecology, Jichi Medical University, Saitama Medical Center, Saitama, Japan.
In Vivo. 2020 Nov-Dec;34(6):3669-3673. doi: 10.21873/invivo.12214.
BACKGROUND/AIM: Data are limited regarding the use of pegfilgrastim in gynaecologic oncology. We evaluated its efficacy for maintaining dose intensity during chemotherapy. PATIENTS AND METHODS: We retrospectively examined the data of 65 women (26 pegfilgrastim users) who underwent primary surgical treatment for stages IB-IV endometrial cancer and had adjuvant chemotherapy containing platinum and taxane; the primary outcome was a relative dose intensity ≥85%. RESULTS: In the pegfilgrastim vs. the control group, body mass index (26.6±5.9 vs. 23.4±4.4), rate of relative dose intensity ≥85% (88.5% vs. 15.4%), plus other adverse event incidences were significantly higher; rate of neutropenia, total hospital visits during chemotherapy (11.0±2.1 vs. 18±5.6 days), unscheduled hospital visits (1.1±1.8 vs. 5.8±5.1 days), and unscheduled granulocyte colony-stimulating factor injections (0.58±1.7 vs. 6.4±5.1 days) were significantly lower. CONCLUSION: Pegfilgrastim can maintain a dose intensity of ≥85% during chemotherapy for the treatment of gynaecologic cancers and decrease hospital-visit frequency.
背景/目的：关于在妇科肿瘤学中使用培非格司亭的数据有限。我们评估了其在维持化疗期间剂量强度的疗效。 患者和方法：我们回顾性地检查了 65 名女性（26 名培非格司亭使用者）的数据，这些女性接受了原发性手术治疗，用于 I B-IV 期子宫内膜癌，并接受了含铂和紫杉烷的辅助化疗；主要结果是相对剂量强度≥85%。 结果：在培非格司亭组与对照组相比，体重指数（26.6±5.9 vs. 23.4±4.4）、相对剂量强度≥85%的发生率（88.5% vs. 15.4%）和其他不良事件发生率显著更高；中性粒细胞减少症发生率、化疗期间总住院天数（11.0±2.1 vs. 18±5.6 天）、非计划住院天数（1.1±1.8 vs. 5.8±5.1 天）和非计划粒细胞集落刺激因子注射天数（0.58±1.7 vs. 6.4±5.1 天）显著降低。 结论：培非格司亭可维持妇科癌症化疗期间的剂量强度≥85%，并降低住院频率。
Taiwan J Obstet Gynecol. 2022-3
Appl Health Econ Health Policy. 2009
J Am Geriatr Soc. 2020-4-3
Am J Prev Med. 2015-12
Crit Rev Oncol Hematol. 2014-10-12
MMWR Morb Mortal Wkly Rep. 2014-6-13
Health Aff (Millwood). 2014-6
Zotero 插件